2025 Q4 -tulosraportti
84 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,41%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 632 | - | - | ||
| 1 368 | - | - | ||
| 199 | - | - | ||
| 297 | - | - | ||
| 300 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sitten · MuokattuStrong phase 3 data for "FRONTIER2". Can add a bit to the share price tomorrow. https://www.prnewswire.com/news-releases/denecimig-mim8-significantly-reduced-annualized-bleeding-rate-in-people-with-hemophilia-a-regardless-of-inhibitor-status-in-phase-3-data-published-in-nejm-302757974.html
·1 t sittenVery good news! This could generate significant revenue and will likely be approved in the USA and Europe during Q3/Q4. Will likely take market share from Roches Hemlibra, which dominates and brings in billions USD.
·3 t sittenInside info: There will be a historic surprise on earnings day :)
·3 t sittenWhat was the bad news today- ·6 t sittenHow do people feel about LLY releasing earnings tomorrow, are they hoping for good or bad results for them? On the one hand, it's great if the competitor is doing badly.
·5 t sittenIf you ask your digital assistant, there won't be any big surprises Expectations for the figures themselves • Revenue and earnings: Analysts (Zacks Consensus) expect revenue of around 17.78 bn. USD and earnings per share (EPS) of 7.26 USD. • Mounjaro and Zepbound: These are still the two "old" familiar products (the injections) that will carry the load. Sales of approx. 7.3 bn. USD are expected for Mounjaro (diabetes) and 4 bn. USD for Zepbound (obesity). • Upward revision? Several analysts (e.g., from Bernstein) speculate that Lilly could exceed expectations and potentially raise their full-year 2026 expectations, which currently stand at revenue between 80-83 bn. USD. 2. Will they comment on the "limited success" with Foundayo? Yes, they will most likely be forced to by analysts during the "earnings call" conference itself. Here are the strategies they are expected to use to explain the figures: • "Inventory build-up and logistics": Lilly will probably point out that they only just received FDA approval in early April, and that shipments have only just started. They will argue that the prescription numbers we are seeing now are merely "early days" and characterized by start-up difficulties in distribution. • Price advantage over volume: Lilly has priced the highest doses of Foundayo at approx. 349 USD/month for self-payers, which is slightly higher than Novo’s pill. They can argue that they prioritize value per patient rather than blindly chasing volume in the first few weeks. • Focus on the future: They will probably highlight their massive investments in production (e.g., their new 6.5 bn. USD facility in Houston) as proof that they are gearing up for a much larger rollout later in the year. • Collaborations: They may mention their new partnerships with, for example, Amazon Pharmacy and telehealth platforms as a way to catch up with Novo’s lead.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
84 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,41%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · MuokattuStrong phase 3 data for "FRONTIER2". Can add a bit to the share price tomorrow. https://www.prnewswire.com/news-releases/denecimig-mim8-significantly-reduced-annualized-bleeding-rate-in-people-with-hemophilia-a-regardless-of-inhibitor-status-in-phase-3-data-published-in-nejm-302757974.html·1 t sittenVery good news! This could generate significant revenue and will likely be approved in the USA and Europe during Q3/Q4. Will likely take market share from Roches Hemlibra, which dominates and brings in billions USD.
- ·3 t sittenInside info: There will be a historic surprise on earnings day :)
- ·3 t sittenWhat was the bad news today
- ·6 t sittenHow do people feel about LLY releasing earnings tomorrow, are they hoping for good or bad results for them? On the one hand, it's great if the competitor is doing badly.·5 t sittenIf you ask your digital assistant, there won't be any big surprises Expectations for the figures themselves • Revenue and earnings: Analysts (Zacks Consensus) expect revenue of around 17.78 bn. USD and earnings per share (EPS) of 7.26 USD. • Mounjaro and Zepbound: These are still the two "old" familiar products (the injections) that will carry the load. Sales of approx. 7.3 bn. USD are expected for Mounjaro (diabetes) and 4 bn. USD for Zepbound (obesity). • Upward revision? Several analysts (e.g., from Bernstein) speculate that Lilly could exceed expectations and potentially raise their full-year 2026 expectations, which currently stand at revenue between 80-83 bn. USD. 2. Will they comment on the "limited success" with Foundayo? Yes, they will most likely be forced to by analysts during the "earnings call" conference itself. Here are the strategies they are expected to use to explain the figures: • "Inventory build-up and logistics": Lilly will probably point out that they only just received FDA approval in early April, and that shipments have only just started. They will argue that the prescription numbers we are seeing now are merely "early days" and characterized by start-up difficulties in distribution. • Price advantage over volume: Lilly has priced the highest doses of Foundayo at approx. 349 USD/month for self-payers, which is slightly higher than Novo’s pill. They can argue that they prioritize value per patient rather than blindly chasing volume in the first few weeks. • Focus on the future: They will probably highlight their massive investments in production (e.g., their new 6.5 bn. USD facility in Houston) as proof that they are gearing up for a much larger rollout later in the year. • Collaborations: They may mention their new partnerships with, for example, Amazon Pharmacy and telehealth platforms as a way to catch up with Novo’s lead.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 632 | - | - | ||
| 1 368 | - | - | ||
| 199 | - | - | ||
| 297 | - | - | ||
| 300 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
84 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. | 6 päivää |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,41%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · MuokattuStrong phase 3 data for "FRONTIER2". Can add a bit to the share price tomorrow. https://www.prnewswire.com/news-releases/denecimig-mim8-significantly-reduced-annualized-bleeding-rate-in-people-with-hemophilia-a-regardless-of-inhibitor-status-in-phase-3-data-published-in-nejm-302757974.html·1 t sittenVery good news! This could generate significant revenue and will likely be approved in the USA and Europe during Q3/Q4. Will likely take market share from Roches Hemlibra, which dominates and brings in billions USD.
- ·3 t sittenInside info: There will be a historic surprise on earnings day :)
- ·3 t sittenWhat was the bad news today
- ·6 t sittenHow do people feel about LLY releasing earnings tomorrow, are they hoping for good or bad results for them? On the one hand, it's great if the competitor is doing badly.·5 t sittenIf you ask your digital assistant, there won't be any big surprises Expectations for the figures themselves • Revenue and earnings: Analysts (Zacks Consensus) expect revenue of around 17.78 bn. USD and earnings per share (EPS) of 7.26 USD. • Mounjaro and Zepbound: These are still the two "old" familiar products (the injections) that will carry the load. Sales of approx. 7.3 bn. USD are expected for Mounjaro (diabetes) and 4 bn. USD for Zepbound (obesity). • Upward revision? Several analysts (e.g., from Bernstein) speculate that Lilly could exceed expectations and potentially raise their full-year 2026 expectations, which currently stand at revenue between 80-83 bn. USD. 2. Will they comment on the "limited success" with Foundayo? Yes, they will most likely be forced to by analysts during the "earnings call" conference itself. Here are the strategies they are expected to use to explain the figures: • "Inventory build-up and logistics": Lilly will probably point out that they only just received FDA approval in early April, and that shipments have only just started. They will argue that the prescription numbers we are seeing now are merely "early days" and characterized by start-up difficulties in distribution. • Price advantage over volume: Lilly has priced the highest doses of Foundayo at approx. 349 USD/month for self-payers, which is slightly higher than Novo’s pill. They can argue that they prioritize value per patient rather than blindly chasing volume in the first few weeks. • Focus on the future: They will probably highlight their massive investments in production (e.g., their new 6.5 bn. USD facility in Houston) as proof that they are gearing up for a much larger rollout later in the year. • Collaborations: They may mention their new partnerships with, for example, Amazon Pharmacy and telehealth platforms as a way to catch up with Novo’s lead.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 632 | - | - | ||
| 1 368 | - | - | ||
| 199 | - | - | ||
| 297 | - | - | ||
| 300 | - | - |
Välittäjätilasto
Dataa ei löytynyt